在患有携带罕见POLD1变异的脂质变异症患者中,基因型-表型异质性
Fieke W Hoff1, Chao Xing2,3,4, Chun-Yuan Huang2
1Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
The Journal of clinical endocrinology and metabolism
|February 26, 2026
概括
与其他POLD1误解变异相比,患有POLD1 p.Ser605del变异的患者表现出更严重的下细胞低成形,聋,前列腺特征和脂质变异综合征 (MDPL).
科学领域:
- 遗传学 遗传学是一种遗传学.
- 人体生理学 人体生理学
- 罕见疾病 罕见疾病
背景情况:
- 部缺血症,耳聋,前列腺特征和脂质缩综合征 (MDPL) 是一种罕见的自体主导性疾病.
- 在POLD1的致病性异构体变异导致MDPL综合征.
- 现有的文献缺乏MDPL的基因型-表型关联.
研究的目的:
- 在14名新患有脂质营养不良的患者中识别和描述POLD1变异.
- 为了比较患有POLD1 p.Ser605del和missense变体的患者之间的临床和代谢表型.
主要方法:
- 对14名患者进行了基因测序 (外体,基因组,候选基因).
- 收集了表型数据,并在变体组之间进行了比较.
- 统计分析包括费舍尔的精确测试和学生的t测试.
主要成果:
- 确定了9种不同的POLD1变种,其中包括3种新型变种.
- 患有p.Ser605del变异的患者表现出明显更高的下腺低成形率,小口,牙拥挤和男性阴性腺体缺陷症.
- 两组之间没有观察到糖尿病或肝肥胖症等代谢并发症的显著差异.
结论:
- 这种POLD1 p.Ser605del变异与更严重的,典型的MDPL表型有关.
- 错误的POLD1变体与非典型的MDPL呈现有关.
- 这项研究确定了POLD1相关疾病的基因型-表型相关性.
相关概念视频
Pleiotropy
43.6K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
43.6K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
77
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
77
Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Principles of Pharmacogenetics: Types of Genetic Variants
59
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
59
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
63
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
63
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
45
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
45


